共 50 条
- [1] An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS576 - TPS576Kim, KevinSaeed, AnwaarSohal, DavendraEdeline, JulienHeo, JeongBhansali, AdityaKumar, ShaheenUngerechts, Guy
- [2] An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Bekaii-Saab, Tanios S.Yarchoan, MarkAhmed, MuneebCohan, David MichaelMa, Wen Wee
- [3] An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Kim, KevinSaeed, AnwaarSohal, DavendraEdeline, JulienHeo, JeongBhansali, AdityaKumar, ShaheenUngerechts, Guy
- [4] A multicenter, open-label study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS649 - TPS649Kim, KevinSaeed, AnwaarIyer, RenukaKim, Richard D.Feun, Lynn G.Kumar, Shaheen
- [5] An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS228 - TPS228Lenz, Heinz-JosefSomasundaram, AshwinLee, Michael SangminSohal, DavendraSafyan, Rachael A.Zhu, MojunJones, Jeremy CliftonBhansali, AdityaKalwar, RozaCho, MayGrothey, Axel
- [6] An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Shepard, Dale RandallAhmed, MuneebBekaii-Saab, Tanios S.Wolff, Johannes
- [7] An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinomaANNALS OF ONCOLOGY, 2023, 34 : S34 - S35Elez, E.Shepard, D.Smolenschi, C.Bekaii-Saab, T.Jac, J.
- [8] An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Raoul, J. L.Finn, R. S.Kang, Y. K.Park, J. W.Harris, R.Coric, V.Donica, M.Walters, I.
- [9] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular CarcinomaCLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098Finn, Richard S.Kang, Yoon-KooMulcahy, MaryPolite, Blase N.Lim, Ho YeongWalters, IanBaudelet, ChristineManekas, DemetriosPark, Joong-Won
- [10] Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2 studyLANCET ONCOLOGY, 2025, 26 (02): : 214 - 226Finn, Richard S.Ryoo, Baek-YeolHsu, Chih-HungLi, DanengBurgoyne, Adam M.Cotter, ChristopherBadhrinarayanan, ShreyaWang, YuleiYin, AnqiEdubilli, Tirupathi RaoMahrus, SamiSecrest, Matthew H.Shemesh, Colby S.Yu, NancyHack, Stephen P.Cha, EdwardGane, Ed